The U.S. Food and Drug Administration (FDA) has granted fast track designation to the cell therapy CABA-201 for organ dysfunction…
Articles by Marisa Wexler, MS
An MRI-based measure called Digital Artery Volume Index, or DAVIX, may help predict the risk that people with scleroderma…
Treatment with FT011 led to clinically meaningful improvements in physical disability and lung function for some scleroderma patients given…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to FT011, an experimental oral medication that…
Arsenic trioxide (ATO) lowered lung inflammation and disease-related alterations to blood vessels in the lungs in a mouse model of…
Treatment with iguratimod, an anti-inflammatory medication, reduced fibrosis (scarring) in cell and mouse models of scleroderma, a study from…
People with scleroderma who report more severe disease symptoms tend to be younger and nonwhite, a new study reports.
People with scleroderma tend to have lower levels of an anti-inflammatory signaling molecule called interleukin-35 (IL-35), a study reports.
About 40% of systemic scleroderma (SSc) patients have subclinical coronary atherosclerosis (SCA), or the buildup of fatty deposits called…
Baricitinib, an anti-inflammatory therapy approved to treat some forms of inflammatory arthritis, showed promising effects in a mouse model of…